Zhen-Yu Wu1,2, Hyun Ho Han3, Hee Jeong Kim2, Jong Won Lee2, Il Yong Chung2, Jisun Kim2, Sae Byul Lee2, Byung-Ho Son2, Jin Sup Eom3, Jae Ho Jung4, Sung- Bae Kim4, Gyungyub Gong5, Hak Hee Kim6, Sei -Hyun Ahn2, BeomSeok Ko7. 1. Department of Breast Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. 2. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 3. Department of Plastic Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 5. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 6. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 7. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. spdoctorko@gmail.com.
Abstract
PURPOSE: We compared oncologic outcomes between breast cancer patients who underwent immediate implant-based breast reconstruction (IBBR) and those who underwent autologous flap reconstruction (AFR) after neoadjuvant chemotherapy (NACT). METHODS: The study group comprised 536 patients with primary breast cancer who underwent NACT followed by immediate IBBR or AFR. After propensity score matching, 138 patients in the IBBR group and 276 patients in the AFR group were selected for comparisons of locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS). RESULTS: No significant differences were observed between the matched groups in locoregional recurrence rates (IBBR vs. AFR: 12.3% vs. 12%; P = 0.915) and distant metastasis (13% vs. 17%; P = 0.293). There was also no significant difference between the groups in LRRFS (P = 0.956), DFS (P = 0.606), DMFS (P = 0.283), or BCSS (P = 0.121). The 5- and 10-year LRRFS rates were 87.6% and 85.9% in the IBBR group, and 87.7% and 86.1% in the AFR group; the 5- and 10-year DFS rates were 79% and 77.5% in the IBBR group, and 77% and 75% in the AFR group; the 5- and 10-year DMFS rates were 85.9% and 85.9% in the IBBR group, and 83.2% and 81.8% in the AFR group; and the 5- and 10-year BCSS rates were 97.8% and 91.3% in the IBBR group, and 91.8% and 86% in the AFR group, respectively. CONCLUSIONS: In this propensity score-matched analysis of oncologic outcomes in breast cancer patients who underwent immediate reconstruction after NACT, no significant differences were observed between the IBBR and AFR groups.
PURPOSE: We compared oncologic outcomes between breast cancerpatients who underwent immediate implant-based breast reconstruction (IBBR) and those who underwent autologous flap reconstruction (AFR) after neoadjuvant chemotherapy (NACT). METHODS: The study group comprised 536 patients with primary breast cancer who underwent NACT followed by immediate IBBR or AFR. After propensity score matching, 138 patients in the IBBR group and 276 patients in the AFR group were selected for comparisons of locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS). RESULTS: No significant differences were observed between the matched groups in locoregional recurrence rates (IBBR vs. AFR: 12.3% vs. 12%; P = 0.915) and distant metastasis (13% vs. 17%; P = 0.293). There was also no significant difference between the groups in LRRFS (P = 0.956), DFS (P = 0.606), DMFS (P = 0.283), or BCSS (P = 0.121). The 5- and 10-year LRRFS rates were 87.6% and 85.9% in the IBBR group, and 87.7% and 86.1% in the AFR group; the 5- and 10-year DFS rates were 79% and 77.5% in the IBBR group, and 77% and 75% in the AFR group; the 5- and 10-year DMFS rates were 85.9% and 85.9% in the IBBR group, and 83.2% and 81.8% in the AFR group; and the 5- and 10-year BCSS rates were 97.8% and 91.3% in the IBBR group, and 91.8% and 86% in the AFR group, respectively. CONCLUSIONS: In this propensity score-matched analysis of oncologic outcomes in breast cancerpatients who underwent immediate reconstruction after NACT, no significant differences were observed between the IBBR and AFR groups.
Entities:
Keywords:
Autologous flap; Breast cancer; Immediate breast reconstruction; Implant; Oncologic safety
Authors: Anne Warren Peled; Frederick Wang; Robert D Foster; Michael Alvarado; Cheryl A Ewing; Hani Sbitany; Laura J Esserman Journal: Ann Surg Oncol Date: 2015-07-14 Impact factor: 5.344
Authors: Jai Min Ryu; Sungmin Park; Hyun-June Paik; Seok Jin Nam; Seok Won Kim; Se Kyung Lee; Jonghan Yu; Soo Youn Bae; Isaac Kim; Sa Ik Bang; Goo-Hyun Mun; Jai-Kyong Pyon; Byung-Joon Jeon; Jeong Eon Lee Journal: Clin Breast Cancer Date: 2016-10-27 Impact factor: 3.225
Authors: Craig A Wengler; Stephanie A Valente; Zahraa Al-Hilli; Neil M Woody; Julia H Muntean; Jame Abraham; Rahul D Tendulkar; Risal Djohan; Colin O'Rourke; Joseph P Crowe; Stephen R Grobmyer Journal: J Surg Oncol Date: 2017-07-11 Impact factor: 3.454
Authors: Mintsje de Boer; Flora E van Leeuwen; Michael Hauptmann; Lucy I H Overbeek; Jan Paul de Boer; Nathalie J Hijmering; Arthur Sernee; Caroline A H Klazen; Marc B I Lobbes; René R W J van der Hulst; Hinne A Rakhorst; Daphne de Jong Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777
Authors: Justin M Broyles; Ethan M Balk; Gaelen P Adam; Wangnan Cao; Monika Reddy Bhuma; Shivani Mehta; Laura S Dominici; Andrea L Pusic; Ian J Saldanha Journal: Plast Reconstr Surg Glob Open Date: 2022-03-11